One of Shire’s top pipeline prospects fails a PhII study among pre­emies

A cou­ple of years ago, when new Shire CEO Flem­ming Orn­skov was sell­ing a bright fu­ture to in­vestors, he care­ful­ly sin­gled out SHP607 as one of the com­pa­ny’s top ex­per­i­men­tal drugs, on track to earn more than $500 mil­lion in an­nu­al sales by 2020.

But he may have to re­vis­it that es­ti­mate af­ter re­port­ing this morn­ing that the pro­tein re­place­ment ther­a­py failed the pri­ma­ry end­point of re­duc­ing the sever­i­ty of retinopa­thy of pre­ma­tu­ri­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.